Shares of Sionna Therapeutics (SION) surged 38.89% in its trading debut on Friday, buoyed by investor enthusiasm for the clinical-stage biopharmaceutical company's successful initial public offering (IPO).
Sionna, which is developing drugs to treat cystic fibrosis, sold 10.6 million shares at $18 per share in its upsized IPO, raising $191 million. The IPO was priced at the top end of its expected range, reflecting strong investor demand for the company's shares.
Based in Waltham, Massachusetts, Sionna is vying for a share of the lucrative cystic fibrosis market, currently dominated by Vertex Pharmaceuticals. The company aims to leverage its expertise in cystic fibrosis therapeutics to develop innovative treatments for the disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.